Article (Scientific journals)
Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 Years.
Boschetti, Gilles; Nancey, Stephane; Daniel, Fady et al.
2016In Inflammatory Bowel Diseases, 22 (12), p. 2924-2932
Peer Reviewed verified by ORBi
 

Files


Full Text
Costs of Crohn's Disease according to...over 10 years-CCFA-PPA.pdf
Publisher postprint (638.76 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] BACKGROUND: To describe the medico-economic characteristics of Crohn's disease (CD), we implemented a multicenter study in France. METHODS: From 2004 to 2006, disease severity states, direct (hospital and extra hospital) and indirect costs were prospectively collected over 1 year in patients with CD naive from anti-tumor necrosis factor alpha (infliximab) at inclusion. Economic valorization was performed from the French Social Insurance perspective, and a statistical modeling over 10 years was performed. RESULTS: In 341 patients, the mean total costs of management were &OV0556;6024 per year (&OV0556;4675 for direct costs). As compared to patients in remission, costs were 4 to 6 times higher in patients in an active period and 19 times higher for patients requiring surgery (SURG). The most important expense items were medical and surgical hospitalizations (56% of total costs), including cost of infliximab (36% of hospitalization costs, i.e., 20% of total costs), indirect costs (22%), and drugs (11%). The statistical modeling over 10 years showed that most of the clinical course was spent in drug-responsive state (54%) with 26% of costs or in remission (32%) with 11% of costs; time spent in a SURG state was small (3.2%) but generated 48% of total costs. CONCLUSIONS: Before the introduction of self-injectable anti-tumor necrosis factor alpha, the most important expenses were supported by hospitalizations, explaining why the most costly states were for patients requiring SURG or dependent on inhospital administrated drugs. Projected data show that most time is spent in a stabilized state with appropriate treatments or in remission, and that costs associated with SURG are high.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Boschetti, Gilles
Nancey, Stephane
Daniel, Fady
Pariente, Benjamin
Lerebours, Eric
Duclos, Bernard
Bourreille, Arnaud
Cadiot, Guillaume
Fumery, Mathurin
Moreau, Jacques
Marteau, Philippe
Bouhnik, Yoram
Louis, Edouard  ;  Université de Liège > Département des sciences cliniques > Hépato-gastroentérologie
Flourie, Bernard
More authors (4 more) Less
Language :
English
Title :
Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 Years.
Publication date :
2016
Journal title :
Inflammatory Bowel Diseases
ISSN :
1078-0998
eISSN :
1536-4844
Publisher :
Lippincott Williams & Wilkins, United States - Maryland
Volume :
22
Issue :
12
Pages :
2924-2932
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 07 December 2017

Statistics


Number of views
103 (1 by ULiège)
Number of downloads
115 (1 by ULiège)

Scopus citations®
 
6
Scopus citations®
without self-citations
5
OpenCitations
 
5

Bibliography


Similar publications



Contact ORBi